切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2018, Vol. 07 ›› Issue (06) : 260 -263. doi: 10.3877/cma.j.issn.2095-3216.2018.06.005

所属专题： 文献；

论著

体外红光照射对血液透析患者血磷水平影响的临床研究
宋康康1, 王涌1, 王远大1, 孙雪峰1, 陈香美1,†()   
  1. 1. 100853　北京，解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室（2011DAV00088）、国家慢性肾病临床医学研究中心，肾脏疾病研究北京市重点实验室
  • 收稿日期:2018-04-11 出版日期:2018-12-28
  • 通信作者: 陈香美
  • 基金资助:
    公益性行业科研专项项目(201502023)

Effect of red light irradiation on blood phosphorus level of hemodialysis patients

Kangkang Song1, Yong Wang1, Yuanda Wang1, Xuefeng Sun1, Xiangmei Chen1,†()   

  1. 1. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing 100853, China
  • Received:2018-04-11 Published:2018-12-28
  • Corresponding author: Xiangmei Chen
  • About author:
    Corresponding author: Chen Xiangmei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

宋康康, 王涌, 王远大, 孙雪峰, 陈香美. 体外红光照射对血液透析患者血磷水平影响的临床研究[J/OL]. 中华肾病研究电子杂志, 2018, 07(06): 260-263.

Kangkang Song, Yong Wang, Yuanda Wang, Xuefeng Sun, Xiangmei Chen. Effect of red light irradiation on blood phosphorus level of hemodialysis patients[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(06): 260-263.

目的

观察体外红光照射联合血液透析对血液透析患者血磷水平的影响。

方法

18例符合入选标准的维持性血液透析患者作为研究对象，随机分为两组，治疗组12例，进行血液透析联合红光照射，对照组6例，进行血液透析联合安慰照射。体外红光照射治疗2 h/次，3次/周，共治疗4周。分别在首次照射前与末次照射后采集血液标本，标本采集时间为透析前、透析1 h、透析2 h，检测患者不同时间血磷水平。同时对两组患者使用的降磷药物及血液净化模式进行对比。对治疗组及对照组患者结果进行统计分析，根据资料分布情况分别采用卡方检验、t检验或非参数检验。

结果

两组患者年龄、性别、原发疾病等基本信息差异无统计学意义。治疗组和对照组患者首次红光照射透析前血磷水平差异无统计学意义[(2.16±0.47) mmol/L与(2.44±0.20 )mmol/L，P＝0.202]，红光照射治疗4周后，治疗组患者透析前血磷水平显著低于对照组[(2.04±0.40) mmol/L与(2.64±0.30) mmol/L，P＝0.007]。两组患者口服降磷药、口服骨化三醇、血液透析滤过、血液灌流频率无统计学差异。

结论

体外红光照射联合血液透析治疗在一定程度上有助于降低血液透析患者血磷水平。

关键词: 红光照射, 维持性血液透析, 血磷
Objective

To observe the effect of red light irradiation on blood phosphorus level of hemodialysis patients.

Methods

Eighteen patients with maintenance hemodialysis were selected as the subjects and randomly divided into two groups. Twelve subjects were in the treatment group, who received hemodialysis combined with red light irradiation. Six subjects were in the control group, who received hemodialysis combined with placebo irradiation. The dose of red light irradiation treatment was 2 hours/time, 3 times/week for a total of 4 weeks. Blood samples were collected before the first irradiation and after the last irradiation. The blood samples were collected before dialysis, at dialysis for 1 hour, and at dialysis for 2 hours for detecting the blood phosphorus level in the patients. The two groups were also compared in the phosphorus-reducing drugs and blood purification modes. Statistical analysis was performed with χ2 test, t-test, or non-parametric test according to the distribution of data.

Results

There was no significant difference between the two groups in the basic data including age, gender, and primary diseases. There was no significant difference in blood phosphorus level between the two groups before the first red light irradiation [(2.16±0.47) mmol/L vs (2.44±0.20) mmol/L, P=0.202]. After 4 weeks of treatment with red light irradiation, the serum phosphorus level in the treatment group was significantly lower than that in the control group [(2.04±0.40) mmol/L vs (2.64±0.30) mmol/L, P=0.007]. The phosphorus binder dose, calcitriol dose, hemodiafiltration frequency, and hemoperfusion frequency were not statistically different between the two groups.

Conclusion

The red light irradiation combined with hemodialysis treatment might be helpful in reducing the blood phosphorus level of hemodialysis patients.

Key words: Red light irradiation, Maintenance hemodialysis, Blood phosphorus
表1 入组患者基本信息[±s/例数(%)]
分组 男性 年龄(岁) 透析龄(月) 原发疾病 血管通路
原发性肾小球疾病 非原发性肾小球疾病 内瘘 中心静脉置管
对照组(n＝6) 4(66.7) 47.0±9.2 59.3±39.6 4(66.7) 2(33.3) 5(83.3) 1(16.7)
治疗组(n＝12) 3(25.0) 53.5±14.7 61.2±42.1 6(50) 6(50) 11(91.7) 1(8.3)
t/χ2值 － 0.984 0.089 － －
P值 0.141 0.340 0.930 0.638 0.999
表2 两组患者血磷检测值(mmol/L)
分组 第1周首次治疗 第4周末次治疗
透析前 透析后1 h 透析后2 h 透析前 透析后1 h 透析后2 h
对照组 2.44±0.20 1.44±0.21 1.16±0.25 2.64±0.30 1.25±0.23 1.14±0.16
治疗组 2.16±0.47 0.76±0.23 0.80±0.27 2.04±0.40 0.86±0.22 0.73±0.25
t值 1.339 6.068 2.650 3.154 2.991 3.339
P值 0.202 <0.001 0.017 0.007 0.010 0.004
表3 两组患者其他降磷治疗对比[±s/M(1/4，3/4)]
分组 每日口服碳酸钙(mg) 每日口服骨化三醇(μg) 血液透析滤过次数 血液灌流次数
对照组 1 800±1 200 0.46±0.40 2(2，2.25) 2.5(1.5，3)
治疗组 1 500±905 0.51±0.45 2(1，2) 2(1，2.75)
t值 0.545 0.240 － －
P值 0.595 0.813 0.192 0.435
[1]
Chang JF, Feng YF, Peng YS, et al. Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients [J]. Medicine (Baltimore), 2014, 93(18): e106.
[2]
Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification [J]. Circ Res, 2000, 87(7): E10-E17.
[3]
Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels [J]. Kidney Int, 2003, 63(3): 1003-1011.
[4]
London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end－stage renal disease: impact on all－cause and cardiovascular mortality [J]. Nephrol Dial Transplant, 2003, 18(9): 1731-1740.
[5]
Hruska KA, Saab G, Mathew S, et al. Renal osteodystrophy, phosphate homeostasis, and vascular calcification [J]. Semin Dial, 2007, 20(4): 309-315.
[6]
Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J]. J Am Soc Nephrol, 2004, 15(8): 2208-2218.
[7]
崔莉，邢国兰，张颖，等. 血液净化方式对维持性血液透析患者血磷及甲状旁腺激素的影响[J]. 河南医学研究，2014, 23(12): 21-24.
[8]
Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium－based versus non－calcium－based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta－analysis [J]. Lancet, 2013, 382(9900): 1268-1277.
[9]
Zhai CJ, Yang XW, Sun J, et al. Efficacy and safety of lanthanum carbonate versus calcium－based phosphate binders in patients with chronic kidney disease: a systematic review and meta－analysis [J]. Int Urol Nephrol, 2015, 47(3): 527-535.
[10]
Di IB, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study [J]. Clin J Am Soc Nephrol, 2012, 7(3): 487-493.
[1] 周敏, 徐阳, 胡莹, 黄先凤. 维持性血液透析患者血清β-CTX、N-MID 和PICP 与冠状动脉钙化的关系及其诊断价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 256-260.
[2] 唐全兴, 周畅. 维持性血液透析患者血清suPAR对动静脉内瘘狭窄发生的诊断价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 74-78.
[3] 冯娟, 詹伟强. 维持性血液透析患者血清热休克蛋白70及簇集蛋白水平与主要不良心血管事件的相关性[J/OL]. 中华肾病研究电子杂志, 2024, 13(01): 34-38.
[4] 许厅, 熊智倩, 刘俪婷, 姜燕, 苏朝江, 刘宗旸. 维持性血液透析患者皮肤瘙痒症的发病机制及治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 334-338.
[5] 兰洁, 薛福平, 任娇娇, 廖智菲, 焦原野, 李静, 王利华. 维持性血液透析患者的住院情况及其影响因素分析[J/OL]. 中华肾病研究电子杂志, 2023, 12(06): 301-307.
[6] 杨静, 顾红叶, 赵莹莹, 孙梦霞, 查园园, 王琪. 老年血液透析患者短期死亡的影响因素及列线图预测模型的预测作用[J/OL]. 中华肾病研究电子杂志, 2023, 12(05): 254-259.
[7] 王珊, 马清, 姚兰, 杨华昱. 老年维持性血透患者叶酸治疗与miR-150-5p血清水平的相关性研究[J/OL]. 中华肾病研究电子杂志, 2023, 12(03): 139-144.
[8] 邵俊侨, 王明. 维持性血液透析患者睡眠障碍的中医药治疗[J/OL]. 中华肾病研究电子杂志, 2023, 12(02): 97-100.
[9] 李峻, 林莉, 王俭梅, 李芬, 刘莉莉, 汪星玉, 丁洁. 黄芪当归贴膏对维持性血液透析患者自体动静脉内瘘的保护作用[J/OL]. 中华肾病研究电子杂志, 2023, 12(02): 87-92.
[10] 徐艺琳, 刘军, 张文颖, 魏敏, 李海伦. 个体化预测维持性血液透析发生动静脉内瘘栓塞风险的列线图模型建立[J/OL]. 中华肾病研究电子杂志, 2023, 12(02): 81-86.
[11] 葛杰, Mali Niroj, 陈广梅, 樊文星, 何佳敏, 曹玲艳. 中性粒细胞/淋巴细胞比值与维持性血液透析患者透析充分性的相关性分析[J/OL]. 中华肾病研究电子杂志, 2022, 11(06): 327-331.
[12] 杨文, 韩宝华, 韩树池, 王慧. 血浆过氧化物还原酶2与维持性血液透析患者预后的相关性研究[J/OL]. 中华肾病研究电子杂志, 2022, 11(03): 139-144.
[13] 蒲蕾, 冯韵霖, 洪大情, 何强, 李贵森, 陈瑾. 蛋白质-能量消耗对血液透析患者预后的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1051-1057.
[14] 李蕾, 柳娟, 陆悦. 血清维生素D水平对维持性血液透析患者下肢肌力减退的预测作用[J/OL]. 中华诊断学电子杂志, 2022, 10(03): 197-201.
[15] 刘倩影, 刘雪彦, 周佩如, 胡申玲, 叶倩呈, 黄洁微. 糖尿病肾病患者血液透析期间低血糖管理的证据总结[J/OL]. 中华肥胖与代谢病电子杂志, 2023, 09(01): 22-27.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号